New Nanoparticle Delivers Hydrogen Gas Directly to Cancer Tumors

Authors
Journal
Applied Materials Today
Year
DOI
10.1016/j.apmt.2018.01.008
Study Type
Cell Culture
Outcome
Positive
Peer Reviewed
Yes
Country
China
Health Condition
Cancer
Body System
Whole Body

TL;DR

Scientists have developed a new type of nanoparticle that can deliver large amounts of hydrogen gas directly to tumors, releasing it on-site in a controlled way to effectively treat cancer.

Key Finding

A new nanoparticle delivery system achieved 1,370 times higher hydrogen gas loading capacity compared to previous hydrogen delivery methods, with controlled release specifically at tumor sites.

Summary

Researchers developed a new nanoparticle (tiny particle) delivery system that can carry and release hydrogen gas directly into tumors. The system uses ammonia borane (a hydrogen-containing compound) loaded into mesoporous silica (a porous material), which releases hydrogen specifically in the acidic environment of cancer cells. In laboratory and animal tests, this approach delivered much more hydrogen to tumors than previous methods and showed promise against cancer cells.

Practical Takeaway

This is early-stage research in cells and animals, not yet tested in humans. While the delivery system shows technical promise for concentrating hydrogen at cancer sites, it remains a laboratory development with no established safety or effectiveness data in people. Much more research would be needed before any clinical application.

Abstract

Hydrogen gas therapy as an emerging and promising therapy strategy has overwhelming advantages especially in bio-safety compared with other gas therapy routes, but is facing a great challenge in the long-term, highly-concentrated, deeply-seated disease site-specific administration of hydrogen gas, owing to its low solubility, high but aimless diffusibility in vivo. Herein, we propose to construct an ammonia borane-loaded mesoporous silica nanomedicine (AB@MSN) to realize the intratumoral high-payload delivery and in situ acid-controlled release of hydrogen gas. The constructed AB@MSN nanomedicine has a superhigh H2 loading capacity (130.6 mg/g, more than 1370 times higher than that of the traditional H2@liposome nanomedicine) and a highly acid-responsive sustained release behavior, exhibiting high anticancer efficacies and high bio-safety in vitro and in vivo. The proposed nanomedicine-based strategy opens a new window for precision high-efficacy hydrogen therapy.